MetaVia Business Summary

MetaVia Inc. (MTVA), formerly NeuroBo Pharmaceuticals, is a clinical-stage biotechnology company focused on developing multi-modal therapies for cardiometabolic diseases. The company currently generates no commercial revenue, operating as a research-intensive entity funded through public equity offerings and strategic partnerships, with a long-term model centered on the licensing and commercialization of its proprietary drug candidates. Its primary business segments are divided by therapeutic focus: the obesity program, led by DA-1726 (a novel GLP1R/GCGR dual agonist), and the metabolic dysfunction-associated steatohepatitis (MASH) program, centered on vanoglipel (DA-1241). MetaVia competes directly with small-cap biotech firms such as Applied Therapeutics (APLT), Traws Pharma (TRAW), and Cadrenal Therapeutics (CVKD), positioning itself as a high-upside clinical player specializing in next-generation oxyntomodulin analogs and GPR119 agonists. The leadership team is headed by President and CEO Hyung Heon Kim, who brings extensive experience from the company’s primary stakeholder and strategic partner, Dong-A ST Co., Ltd. He is supported by Chief Financial Officer Marshall H. Woodworth, a veteran finance executive with previous leadership roles at Nevakar, Braeburn Pharmaceuticals, and Furiex Pharmaceuticals, and Chief Scientific Officer Dr. Mi-Kyung Kim. The company’s strategic direction is overseen by Chairman Andrew Koven, whose pedigree includes executive tenures at Aralez Pharmaceuticals and Auxilium Pharmaceuticals. MetaVia is notably backed by Dong-A ST Co., Ltd., which maintains a majority ownership stake of approximately 55%, providing critical institutional support and a pipeline of licensed assets from the South Korean pharmaceutical giant.